DiaMedica Initiates New Type 1 Diabetes Program


DiaMedica Inc., a Canadian biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders, announced the initiation of a type 1 diabetes program following the acquisition of Sanomune. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously shown to have clinical efficacy for type 2 diabetes. The initial results from this study, on animals, showed that DM-99 was able to reduce fasting blood glucose, an indication that new beta cells may be created or that existing beta cells are being protected.

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x